What is claimed is:

1. An alcohol-resistant controlled release oral pharmaceutical composition of lorazepam, comprising

a sustained release drug-containing core comprising lorazepam in a sustained release formulation comprising a controlled release polymer;

a delayed release drug-containing core comprising a sustained release drug-containing core comprising lorazepam in a sustained release formulation comprising a controlled release polymer and an enteric coating surrounding the sustained release drug-containing core; and

a coated substrate surrounded by an alcohol-resistant coating, wherein the substrate of the coated substrate is at least one of the sustained release drug-containing core, the delayed release drug-containing core, or a dosage form comprising both of the sustained release drug-containing core and the delayed release drug-containing core, wherein the alcohol-resistant coating comprises one or more ethanol-insoluble components selected from the group consisting of carbomers, polyethylene oxide polymers, xanthan gum, and alginate;

wherein the amount of lorazepam released from the coated substrate is 75% or less than the amount of lorazepam released from the uncoated substrate, when measured by dissolution testing at 37.0 ± 0.5 °C and 100 rpm for two hours in an acidic ethanolic aqueous solution comprising 40% ethanol and 0.1 N HCl solution in accordance with USP <711>, and

wherein the amount of lorazepam released from the coated substrate is ± 25% or less, ± 20% or less, ± 10% or less, ± 5% or less, or ± 1% or less, as compared to the amount of lorazepam released from a corresponding substrate without the alcohol-resistant coating, when measured by dissolution testing at 37.0 ± 0.5 °C and 100 rpm for two hours in an aqueous 0.1 N HCl solution, in accordance with USP <711>.

2. The composition of claim 1, wherein the one or more ethanol-insoluble components is selected from the group consisting of xanthan gum and alginate.

3. The composition of claim 1, wherein the one or more ethanol-insoluble components is sodium carboxymethylcellulose or sodium alginate.

4. The composition of claim 1, wherein the one or more ethanol-insoluble components is xanthan gum.

5. The composition of any one of claims 1 to 4, wherein the weight:weight ratio of alcohol-resistant coating to substrate of the coated substrate is at least 1:10; from 1:10 to 3:1; from 1:10 to 1:1; or selected from the group consisting of at least 1:10, at least 1.5:10, at least 2:10, at least 2.5:10, at least 3:10, at least 3.5:10, at least 4:10, at least 4.5:10, at least 5:10, at least 5.5:10, at least 6:10, at least 6.5:10, at least 7:10, at least 7.5:10, at least 8:10, at least 8.5:10, at least 9:10, at least 9.5:10, and at least 1:1.

6. The composition of any one of claims 1 to 5, wherein the coated substrate releases less than 50%, less than 40%, less than 25%, less than 10% , or less than 1% by weight of lorazepam in the presence of alcohol as compared to the amount of lorazepam released by a corresponding substrate without the alcohol-resistant coating, when measured by dissolution testing at 37.0 ± 0.5 °C and 100 rpm for two hours in an acidic ethanolic solution comprising 40% ethanol and 0.1 N HCl solution.

7. The composition of any one of claims 1 to 6, wherein each of the cores is a particle, a granule, a pellet, or a beadlet.

8. The composition of any one of claims 1 to 7, wherein the coated substrate is a dosage form that is a tablet or a capsule.

9. The composition of any one of claims 1 to 8, wherein the coated substrate is the sustained release drug-containing core or a combination of the sustained release drug-containing core and the delayed release drug-containing core.

10. The composition of claim 9, wherein the alcohol-resistant coating is interior to the enteric coating.

11. The composition of claim 9, wherein the alcohol-resistant coating is exterior to the enteric coating.

12. The composition of any one of claims 1 to 6, wherein the coated substrate is formulated in a tablet or filled into a capsule shell, and wherein the tablet or capsule shell optionally is surrounded by an alcohol-resistant coating.

13. The composition of any one of claims 1 to 6, wherein the substrate is in the form of a tablet or capsule surrounded by an alcohol-resistant coating.

14. The composition of any one of claims 1 to 13, wherein the coated substrate is contained within a sachet package.

15. The composition of claim 1, comprising:

coated sustained release beadlets comprising (i) beadlets comprising lorazepam in a sustained release formulation surrounded by an alcohol-resistant coating, wherein the alcohol-resistant coating is less soluble in ethanol than in water; and

coated delayed sustained release beadlets comprising (i) beadlets comprising lorazepam in a sustained release formulation, (ii) an enteric coating surrounding the beadlets, and (iii) an alcohol-resistant coating surrounding the beadlets, wherein the alcohol-resistant coating is less soluble in ethanol than in water, and wherein the alcohol-resistant coating may be interior to or exterior to the enteric coating.

16. The composition of claim 1, comprising:

sustained release beadlets comprising lorazepam in a sustained release formulation; and

delayed sustained release beadlets comprising (i) beadlets comprising lorazepam in a sustained release formulation, (ii) an enteric coating surrounding the beadlets, formulated in a capsule or tablet, wherein the capsule or tablet is surrounded by an alcohol-resistant coating, wherein the alcohol-resistant coating is less soluble in ethanol than in water, and wherein the alcohol-resistant coating may be interior to or exterior to the enteric coating.

17. The composition of claim 1, further comprising lorazepam in an immediate release formulation.

18. The composition of claim 1, wherein the controlled release polymer is a hydroxypropyl methylcellulose, a polyacrylate, a polyvinyl alcohol, or a polyethylene oxide.

19. The pharmaceutical composition according to any of the preceding claims for use in reducing the risks of concomitant consumption of lorazepam and alcohol, comprising administering the pharmaceutical composition to a subject in need thereof.